美国生物制药公司CorMedix Inc.(CRMD)周五盘中股价大涨5.11%,报收于10.50美元/股,引发市场关注。
分析人士认为,该股价上涨或与机构对公司主打产品DefenCath的看好有关。该产品专门用于预防和治疗感染性疾病和炎症性疾病,已处于商业化的最后阶段。如果能顺利推向美国及其他主要市场,将为公司带来不菲收益。
此外,公司最新财报显示营收同比有所增长,达到1146万美元。尽管净利润仍为负值,但亏损幅度有所收窄。在分析师看来,财报数据总体向好,增强了投资者对公司长期发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.